Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Allegra · 1 trial · 1 indication
Acoustic rhinometry: a technique intended for assessment of the geometry of nasal cavity and nasopharynx and for evaluating nasal obstruction. At each time point, there were 2 acoustic rhinometry measurements taken, one for each nostril. Mean of the left and right nostril measurements was taken as measurement at each time point. Minimum Cross-Sectional Area (Amin) at Baseline was defined as mean of 3, 'post-diluent, pre-allergen challenge' measures for each intervention period at 2 hours (hrs) 10 minutes (min), 2 hrs 25 min and 2 hrs 40 min post PF-03654746/placebo dose. Amin 'post-allergen challenge' measures recorded at 2 hrs 55 min, 3 hrs 10 min and 3 hrs 25 min post PF-03654746/placebo dose for each intervention period was averaged to derive single 'post-allergen challenge' value. Amin proportion was defined as ratio of 'post-allergen challenge' value and 'Baseline/pre-allergen challenge value'. Diluent used was saline and allergen was short ragweed extract.
Acoustic rhinometry: a technique intended for assessment of the geometry of nasal cavity and nasopharynx and for evaluating nasal obstruction. At each time point, there were 2 acoustic rhinometry measurements taken, one for each nostril. Mean of the left and right nostril measurements was taken as measurement at each time point. Nasal volume at Baseline was defined as mean of 3, 'post-diluent, pre-allergen challenge' measures for each intervention period at 2 hrs 10 min, 2 hrs 25 min and 2 hrs 40 min post PF-03654746/placebo dose. Nasal volume 'post-allergen challenge' measures recorded at 2 hrs 55 min, 3 hrs 10 min and 3 hrs 25 min post PF-03654746/placebo dose for each intervention period was averaged to derive single 'post-allergen challenge' value. Nasal volume proportion was defined as ratio of 'post-allergen challenge' value and 'Baseline/pre-allergen challenge value'. Diluent used was saline and allergen was short ragweed extract.
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | - |
| Allegra | ACTIVE_COMPARATOR | - |
| Allegra-D | ACTIVE_COMPARATOR | - |
| PF-03654746 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | A single oral dose of Placebo is dosed during the study in order to ascertain the effect of placebo on measures and in order to maintain the blind of the other drugs. |
| Allegra | DRUG | A single oral dose of Allegra is dosed to subjects in combination with PF-03654746. |
| Allegra-D | DRUG | A single oral dose of Allegra-D is dosed to subjects as an active comparator. |
| PF-03654746 | DRUG | A single oral dose of PF-03654746 is the investigational drug being studied. |
Inclusion Criteria: * Male or female subjects 19-55 years with allergic rhinitis requiring treatment within the previous 2 years. * Subjects that respond to a ragweed nasal allergen challenge at screening. Exclusion Criteria: * History of asthma or FEV1 \< 80% predicted. * Significant concomitant...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Eli Lilly and Company | LLY | 1 | PHASE3 | LY3650150, Standard therapy for INCS |
| Polyrizon Ltd. | PLRZ | 1 | N/A | Undisclosed |
| Regeneron Pharmaceuticals, Inc. | REGN | 1 | - | Undisclosed |
Allegra is a small molecule drug being developed for allergic rhinitis. It is currently in Phase 2 clinical development and is being studied as a decongestant in patients with allergic rhinitis following a nasal allergen challenge.
Allegra is being developed by Pfizer, Inc., which is publicly traded under the ticker symbol PFE. The drug is currently in Phase 2 clinical development for the treatment of allergic rhinitis.
Allegra is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 2 clinical trial has been completed, and no trials are currently active.
Allegra has one completed Phase 2 clinical trial with the identifier NCT00562120. This trial was a randomized, double-blind, placebo-controlled study that enrolled 21 participants in the United States to test Allegra as a decongestant in patients with allergic rhinitis following a nasal allergen challenge.
Allegra is not FDA approved. It is an investigational drug currently in Phase 2 clinical development for allergic rhinitis. The drug has completed one Phase 2 clinical trial, but it has not yet received regulatory approval.